Abstract

Canine and feline lymphoma is a common hematopoietic malignancy that generally responds well to systemic chemotherapy. In dogs, several recent investigations have underscored the beneficial effects of adjunctive radiation therapy for the treatment of multicentric lymphoma. With the emergence of effective immunotherapeutic agents against non-Hodgkin's lymphoma in people, some of these specific targeted immunotherapeutics may soon be a viable option for treating lymphoid malignancies in dogs. Although the effective and durable treatment of feline lymphoma remains disappointing, the identification of environmental etiologic factors may help to shape future recommendations for disease prevention. It is only reasonable to assume that as our fundamental understanding of lymphoid malignancies grows, better diagnostic tools, predictive markers, and therapeutic options will also emerge.

Original languageEnglish (US)
Pages (from-to)455-471
Number of pages17
JournalVeterinary Clinics of North America - Small Animal Practice
Volume33
Issue number3
DOIs
StatePublished - May 2003

Fingerprint

lymphoma
Lymphoma
Felidae
dogs
Dogs
cats
non-Hodgkin lymphoma
disease prevention
radiotherapy
Hematologic Neoplasms
Non-Hodgkin's Lymphoma
drug therapy
Canidae
Neoplasms
Radiotherapy
Therapeutics
Drug Therapy
therapeutics
environmental factors

ASJC Scopus subject areas

  • Small Animals

Cite this

Lymphoma updates. / Fan, Timothy M.

In: Veterinary Clinics of North America - Small Animal Practice, Vol. 33, No. 3, 05.2003, p. 455-471.

Research output: Contribution to journalReview article

@article{bdb7a2c0c60c41d7a8d948efc2323a1d,
title = "Lymphoma updates",
abstract = "Canine and feline lymphoma is a common hematopoietic malignancy that generally responds well to systemic chemotherapy. In dogs, several recent investigations have underscored the beneficial effects of adjunctive radiation therapy for the treatment of multicentric lymphoma. With the emergence of effective immunotherapeutic agents against non-Hodgkin's lymphoma in people, some of these specific targeted immunotherapeutics may soon be a viable option for treating lymphoid malignancies in dogs. Although the effective and durable treatment of feline lymphoma remains disappointing, the identification of environmental etiologic factors may help to shape future recommendations for disease prevention. It is only reasonable to assume that as our fundamental understanding of lymphoid malignancies grows, better diagnostic tools, predictive markers, and therapeutic options will also emerge.",
author = "Fan, {Timothy M.}",
year = "2003",
month = "5",
doi = "10.1016/S0195-5616(03)00005-6",
language = "English (US)",
volume = "33",
pages = "455--471",
journal = "Veterinary Clinics of North America - Small Animal Practice",
issn = "0195-5616",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Lymphoma updates

AU - Fan, Timothy M.

PY - 2003/5

Y1 - 2003/5

N2 - Canine and feline lymphoma is a common hematopoietic malignancy that generally responds well to systemic chemotherapy. In dogs, several recent investigations have underscored the beneficial effects of adjunctive radiation therapy for the treatment of multicentric lymphoma. With the emergence of effective immunotherapeutic agents against non-Hodgkin's lymphoma in people, some of these specific targeted immunotherapeutics may soon be a viable option for treating lymphoid malignancies in dogs. Although the effective and durable treatment of feline lymphoma remains disappointing, the identification of environmental etiologic factors may help to shape future recommendations for disease prevention. It is only reasonable to assume that as our fundamental understanding of lymphoid malignancies grows, better diagnostic tools, predictive markers, and therapeutic options will also emerge.

AB - Canine and feline lymphoma is a common hematopoietic malignancy that generally responds well to systemic chemotherapy. In dogs, several recent investigations have underscored the beneficial effects of adjunctive radiation therapy for the treatment of multicentric lymphoma. With the emergence of effective immunotherapeutic agents against non-Hodgkin's lymphoma in people, some of these specific targeted immunotherapeutics may soon be a viable option for treating lymphoid malignancies in dogs. Although the effective and durable treatment of feline lymphoma remains disappointing, the identification of environmental etiologic factors may help to shape future recommendations for disease prevention. It is only reasonable to assume that as our fundamental understanding of lymphoid malignancies grows, better diagnostic tools, predictive markers, and therapeutic options will also emerge.

UR - http://www.scopus.com/inward/record.url?scp=0037742272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037742272&partnerID=8YFLogxK

U2 - 10.1016/S0195-5616(03)00005-6

DO - 10.1016/S0195-5616(03)00005-6

M3 - Review article

C2 - 12852231

AN - SCOPUS:0037742272

VL - 33

SP - 455

EP - 471

JO - Veterinary Clinics of North America - Small Animal Practice

JF - Veterinary Clinics of North America - Small Animal Practice

SN - 0195-5616

IS - 3

ER -